ARS CRO will register a well-studied tableted generic drug in Russia based on scientific literature review of preclinical and clinical research of the product. ARS will provide a pathway for marketing authorization of the drug without conducting own studies by the pharmaceutical company. The Sponsor will save time and financial resources.